{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:00:18Z","timestamp":1790596818497,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The RAS-RAF-MEK-ERK signaling pathway plays a key regulatory role in the survival and proliferation of mammalian cells. Accordingly, deregulated activation of this cascade by a mutated K-RAS (mutK-RAS) is a major cause of cancer initiation and progression. These findings led to the development of synthetic inhibitors that target the mutK-RAS protein, as a therapeutic approach. However, the challenging design of synthetic compounds that effectively and selectively inhibit the mutK-RAS, and the high prevalence of acquired resistance to the mutK-RAS inhibitors, motivated also the development of synthetic inhibitors to downstream effectors of mutK-RAS, such as ERK1\/2. Unfortunately, these putative anti-cancer drugs also exhibited limited efficacy, due to the reactivation of the inhibited ERK1\/2 kinases by their deregulated upstream activators, RAF and MEK, an effect that led to an acquired resistance. Recently, several studies reported the targeting of novel, mutK-RAS-RAF-MEK-ERK sustaining proteins whose downregulation led to ERK1\/2 inhibition, without subsequent ERK1\/2 reactivation and without acquired resistance. The knockdown or inhibition of the intracellular tyrosine kinase FER, whose expression level is linked to poor prognosis of cancer patients, led to significant and persistent inhibition of ERK1\/2, without subsequent reactivation. In an additional report, myotrophin (MTPN) was identified as a crucial mediator of ERK1\/2 oncogenic activation. Accordingly, knockdown of MTPN blocked ERK1\/2 activity without inducing later reactivation, or acquired resistance of these kinases. Here, we discuss these novel findings, which could pave the way for novel intervention approaches with deregulated ERK1\/2 activation, with significant ramifications for the therapeutic targeting of the key K-RAS-ERK1\/2 oncogenic pathway.<\/jats:p>","DOI":"10.3389\/fonc.2026.1948976","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:22:01Z","timestamp":1790594521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking the ERK1\/2 negative feedback loop: avoiding reactivation and acquisition of resistance by ERK1\/2 to anti-cancer agents"],"prefix":"10.3389","volume":"16","author":[{"given":"Orel","family":"Slotki-Itzchakov","sequence":"first","affiliation":[{"name":"The Mina and Everard Goodman Faculty of Life-Sciences, Bar-Ilan University","place":["Ramat-Gan, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Shpungin","sequence":"additional","affiliation":[{"name":"The Mina and Everard Goodman Faculty of Life-Sciences, Bar-Ilan University","place":["Ramat-Gan, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Nir","sequence":"additional","affiliation":[{"name":"The Mina and Everard Goodman Faculty of Life-Sciences, Bar-Ilan University","place":["Ramat-Gan, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","article-title":"Kras: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0122","article-title":"Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer","volume":"22","author":"Khan","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0347","article-title":"A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma","volume":"2","author":"Collisson","year":"2012","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/s41467-020-16123-w","article-title":"Sequential Ras\/MAPK and PI3K\/AKT\/mTOR pathways recruitment drives basal extrusion in the prostate-like gland of Drosophila","volume":"11","author":"Rambur","year":"2020","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","article-title":"Erk1\/2 inhibitors: new weapons to inhibit the RAS-regulated RAF-MEK1\/2-ERK1\/2 pathway","volume":"187","author":"Kidger","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.08.001","article-title":"Targeting pathological ERK1\/2 signaling in cancer and beyond","volume":"32","author":"Schanbacher","year":"2026","journal-title":"Trends Mol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adr3738","article-title":"Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer","volume":"18","author":"Aust","year":"2025","journal-title":"Sci Signal"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.9.9.7601337","article-title":"The MAPK signaling cascade","volume":"9","author":"Seger","year":"1995","journal-title":"FASEB J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113386","article-title":"Research progress of MEK1\/2 inhibitors and degraders in the treatment of cancer","volume":"218","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2015-lb-055","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.160","article-title":"Mechanisms of acquired resistance to ERK1\/2 pathway inhibitors","volume":"32","author":"Little","year":"2013","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1038\/ncomms7685","article-title":"The nuclear translocation of ERK1\/2 as an anticancer target","volume":"6","author":"Plotnikov","year":"2015","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1947601911407328","article-title":"The ERK cascade: distinct functions within various subcellular organelles","volume":"2","author":"Wortzel","year":"2011","journal-title":"Genes Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.11.055","article-title":"Regulation of Raf-1 by direct feedback phosphorylation","volume":"17","author":"Dougherty","year":"2005","journal-title":"Mol Cell"},{"key":"B18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-5793(94)00475-7","article-title":"Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1)","volume":"346","author":"Brunet","year":"1994","journal-title":"FEBS Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.3.1594-1602.1994","article-title":"Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation","volume":"14","author":"Rossomando","year":"1994","journal-title":"Mol Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2297-8","article-title":"Negative feedback regulation of the ERK1\/2 MAPK pathway","volume":"73","author":"Lake","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/kinasesphosphatases4010004","article-title":"Balancing the edge: phosphatases as homeostatic buffers of oncogenic kinase signaling in cancer","volume":"4","author":"Ehm","year":"2026","journal-title":"Kinases Phosphatases"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.20892\/j.issn.2095-3941.2017.0107","article-title":"Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer","volume":"15","author":"Ahmad","year":"2018","journal-title":"Cancer Biol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m406720200","article-title":"Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal","volume":"279","author":"Karlsson","year":"2004","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.25.5.1830-1845.2005","article-title":"Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5","volume":"25","author":"Mandl","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1042\/bj20071512","article-title":"Negative-feedback regulation of FGF signalling by DUSP6\/MKP-3 is driven by ERK1\/2 and mediated by Ets factor binding to a conserved site within the DUSP6\/MKP-3 gene promoter","volume":"412","author":"Ekerot","year":"2008","journal-title":"Biochem J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq020","article-title":"Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells","volume":"31","author":"Zhang","year":"2010","journal-title":"Carcinogenesis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m808490200","article-title":"Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation","volume":"284","author":"Jurek","year":"2009","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.25.2.854-864.2005","article-title":"Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3\/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation","volume":"25","author":"Marchetti","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00448","article-title":"P2X7 nucleotide and EGF receptors exert dual modulation of the dual-specificity phosphatase 6 (MKP-3) in granule neurons and astrocytes, contributing to negative feedback on ERK signaling","volume":"10","author":"Queipo","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1119","article-title":"First-in-class ERK1\/2 inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41698-025-01049-7","article-title":"Exosome-transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA\/Hippo axis","volume":"9","author":"Liu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B32","article-title":"Clinicopathological significances of Feline sarcoma-related protein and beta2-adrenoceptor expression in pancreatic ductal adenocarcinomas","volume":"12","author":"Luo","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04890-1","article-title":"Fer-mediated activation of the Ras-MAPK signaling pathway drives the proliferation, migration, and invasion of endometrial carcinoma cells","volume":"479","author":"Shen","year":"2024","journal-title":"Mol Cell Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1427029","article-title":"Fer governs mTORC1 regulating pathways and sustains viability of pancreatic ductal adenocarcinoma cells","volume":"14","author":"Schrier","year":"2024","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41467-017-00832-w","article-title":"A novel Fer\/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells","volume":"8","author":"Elkis","year":"2017","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.08.001","article-title":"Fer kinase sustains the activation level of ERK1\/2 and increases the production of VEGF in hypoxic cells","volume":"17","author":"Salem","year":"2005","journal-title":"Cell Signal"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-026-03795-9","article-title":"MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC","volume":"45","author":"Li","year":"2026","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091512","article-title":"Targeting the KRAS oncogene for patients with metastatic colorectal cancer","volume":"17","author":"Ruoyu","year":"2025","journal-title":"Cancers"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/0929867329666220819115849","article-title":"Immune checkpoint inhibitors: recent clinical advances and future prospects","volume":"30","author":"Banday","year":"2023","journal-title":"Curr Med Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2026.109775","article-title":"Erk1\/2-targeted cancer therapies: recent advances, potential drug resistance, and applicability analysis of emerging technologies","volume":"175","author":"Mao","year":"2026","journal-title":"Bioorg Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1948976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:22:02Z","timestamp":1790594522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1948976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1948976"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1948976","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1948976"}}